On January 15, the 2026 Provincial Drug Administration Work Conference was held in Nanjing. The reporter learned from the conference that in 2025, Jiangsu received 427 new drugs approved for marketing, including 17 innovative drugs, accounting for 22.37% of the country's total, 566 Class III medical devices, and 2,064 Class II medical devices, all ranking first in the country. Fifteen new innovative medical devices were approved, accounting for 19.74% of the country's total, and the number jumped to the top of the country. In 2026, Jiangsu will combine full-chain drug safety supervision with artificial intelligence to promote a high level of drug safety and high-quality industrial development.

On January 15, the 2026 Provincial Drug Administration Work Conference was held in Nanjing. The reporter learned from the conference that in 2025, Jiangsu received 427 new drugs approved for marketing, including 17 innovative drugs, accounting for 22.37% of the country's total, 566 Class III medical devices, and 2,064 Class II medical devices, all ranking first in the country. Fifteen new innovative medical devices were approved, accounting for 19.74% of the country's total, and the number jumped to the top of the country. In 2026, Jiangsu will combine full-chain drug safety supervision with artificial intelligence to promote a high level of drug safety and high-quality industrial development.